A recent network meta-analysis of α-blockers, antibiotics and other drug therapies for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) found that they provided modest-to-no benefit for this condition, confirming previous findings. However, a casual reading of the article may give a false impression of the efficacy and appropriateness of these drugs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity
Stem Cell Research & Therapy Open Access 25 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anothaisintawee, T. et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 305, 78–86 (2011).
Song, F. et al. Methodological problems in the use of indirect comparisons for evaluations healthcare interventions: survey of published systematic reviews. BMJ 338, b1147 (2009).
Curtis Nickel, J., Baranowski, A. P., Pontari, M., Berger, R. E. & Tripp, D. A. Management of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome who have failed traditional management. Rev. Urol. 9, 63–72 (2007).
Nickel, J. C. et al. Alfuzosin and symptoms of chronic prostatitis–chronic pelvic pain syndrome. N. Engl. J. Med. 359, 2663–2673 (2008).
Alexander, R. B. et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann. Intern. Med. 141, 581–589 (2004).
Shoskes, D. A., Nickel, J. C. & Kattan, M. W. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 75, 1249–1253 (2010).
Anderson, R. U., Wise, D., Sawyer, T. & Chan, C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J. Urol. 174, 155–160 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Anderson, R., Nathanson, B. Drug therapies for CP/CPPS: help or hype?. Nat Rev Urol 8, 236–237 (2011). https://doi.org/10.1038/nrurol.2011.51
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.51
This article is cited by
-
IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity
Stem Cell Research & Therapy (2021)
-
Equal Improvement in Men and Women in the Treatment of Urologic Chronic Pelvic Pain Syndrome Using a Multi-modal Protocol with an Internal Myofascial Trigger Point Wand
Applied Psychophysiology and Biofeedback (2016)
-
Chronic Pelvic Pain Syndrome: Reduction of Medication Use After Pelvic Floor Physical Therapy with an Internal Myofascial Trigger Point Wand
Applied Psychophysiology and Biofeedback (2015)
